Study: NCT00886613

Adverse event: Headache
Serious: no
Organ System: Nervous system disorders
Frequency: 1 affected / 41 at risk

Adverse event: Injection site erythema (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 11 affected / 41 at risk

Adverse event: Injection site erythema (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 36 affected / 41 at risk

Adverse event: Injection site induration (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 6 affected / 41 at risk

Adverse event: Injection site induration (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 19 affected / 41 at risk

Adverse event: Injection site pain (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 4 affected / 41 at risk

Adverse event: Injection site pain (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 5 affected / 41 at risk

Adverse event: Injection site pruritis (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 2 affected / 41 at risk

Adverse event: Headache
Serious: no
Organ System: Nervous system disorders
Frequency: 2 affected / 39 at risk

Adverse event: Injection site erythema (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 18 affected / 39 at risk

Adverse event: Injection site erythema (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 36 affected / 39 at risk

Adverse event: Injection site induration (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 16 affected / 39 at risk

Adverse event: Injection site induration (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 18 affected / 39 at risk

Adverse event: Injection site pain (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 21 affected / 39 at risk

Adverse event: Injection site pain (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 8 affected / 39 at risk

Adverse event: Injection site pruritis (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 2 affected / 39 at risk

Adverse event: Rash
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Frequency: 3 affected / 39 at risk

Adverse event: Rash vesicular
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Frequency: 1 affected / 39 at risk

Adverse event: Miliaria
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Frequency: 2 affected / 39 at risk

Adverse event: Headache
Serious: no
Organ System: Nervous system disorders
Frequency: 2 affected / 39 at risk

Adverse event: Injection site erythema (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 7 affected / 39 at risk

Adverse event: Injection site erythema (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 28 affected / 39 at risk

Adverse event: Injection site induration (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 4 affected / 39 at risk

Adverse event: Injection site induration (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 17 affected / 39 at risk

Adverse event: Injection site pain (Vaccination)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of V212, Zostavax™ or placebo.
Frequency: 2 affected / 39 at risk

Adverse event: Injection site pain (Skin test)
Serious: no
Organ System: General disorders
Notes: Injection site reaction following administration of the skin test.
Frequency: 2 affected / 39 at risk

Adverse event: Rash
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Frequency: 1 affected / 39 at risk

Adverse event: Rash vesicular
Serious: no
Organ System: Skin and subcutaneous tissue disorders
Frequency: 2 affected / 39 at risk